Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction
about
Heart failure with preserved ejection fraction: emerging drug strategiesUnderstanding the epidemic of heart failure: past, present, and futureRisk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.Alterations in cardiac structure and function in hypertensionElevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population.Noncardiac comorbidities in heart failure with reduced versus preserved ejection fractionObesity and sleep apnea are independently associated with adverse left ventricular remodeling and clinical outcome in patients with atrial fibrillation and preserved ventricular function.Clinical prediction of incident heart failure risk: a systematic review and meta-analysis.Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study.Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice.Consumption of fried foods and risk of heart failure in the physicians' health study.Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction.Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge.Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure SubtypesImpact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis).Pathological ventricular remodeling: therapies: part 2 of 2.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.The emerging epidemic of heart failure with preserved ejection fraction.Serial galectin-3 and future cardiovascular disease in the general population.Heart Failure in Women--Insights from the Framingham Heart Study.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal WomenPharmacotherapy of heart failure with preserved ejection fraction.Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.Electrocardiographic Predictors of Heart Failure With Reduced Versus Preserved Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis.Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.Sex steroids in relation to cardiac structure and function in men.Ambulatory Blood Pressure Parameters and Heart Failure With Reduced or Preserved Ejection Fraction in Elderly Treated Hypertensive Patients.Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure.Phenotype-Specific Association of Single-Nucleotide Polymorphisms with Heart Failure and Preserved Ejection Fraction: a Genome-Wide Association Analysis of the Cardiovascular Health Study.The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction.Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes.Sex Differences in Metabolic Cardiomyopathy.Relationship Between Age and Trajectories of Rehospitalization Risk in Older Adults.
P2860
Q24595118-D3ECA1C2-8A4A-45B2-9DB0-596797FC192DQ26996486-05E59A40-59FF-4D6F-94DA-8F8DB908A4AAQ30234586-69A3DBE2-2184-433D-B69A-929D1A7F84C4Q33732380-4EB38140-E5E0-4181-992B-7A8FEE36098FQ34103605-D3C61C62-E21D-4067-87E2-E69E55E68D02Q34625223-6704F34E-A53D-499D-BC23-8906D7B882DAQ35120694-1A916DB7-9EB3-4E17-A69C-90559ECAF51CQ35399799-004D2C2A-A0A2-451E-AB96-7854EB04B223Q35630009-2FA6F6A2-0C13-4437-99BF-FA13BAE36B8CQ35690501-6EC0451C-CD9C-4CE9-97F7-5ED2ECCC4DFBQ35690546-6DBB2CF2-C941-4C5B-839C-574C2264381FQ35883067-75EB4D93-7519-4363-A038-550BB423EB59Q36085742-82C4148D-B3C7-4488-BC9E-4026EBCF0191Q36303452-C303EC2F-8216-48A7-9585-CDA3D72AE783Q36481310-E68BBE94-351E-470A-A347-AB5A761E8FF9Q36877540-166320AF-885D-4697-93C1-5ADD859FA62CQ36992652-A5188B83-BD16-4F6E-9546-90D0B719140FQ37207790-B94964E7-1E31-42A7-BAF5-0AB5B7B3ACD4Q37312758-0B56AFB7-B9A0-4D7F-9F5E-0ECF24FA49DBQ37366826-4DA655B8-0E52-4FE3-9EA7-D136E5C26D21Q37407880-0267A48D-357B-4022-9865-43A3F6725166Q37580709-35E9C1B6-B78C-4E76-80C2-DF88D4E34126Q37637447-A9CD8987-6CAA-4F24-8A4A-C615CF10B568Q38194209-4C15EE01-1A53-40F9-ADA2-5F95FA5A654DQ38261197-8B65AB41-AB34-4121-890C-BAA1D6CF66EDQ38387058-EA71935F-B814-4543-925B-41B8405B4989Q38425861-9211C8DC-DEC8-4181-AF64-D1B9D20F685CQ38658569-3619CB91-55E9-459F-9636-DC6A5F1BC5B3Q38678700-B333B8C2-A076-4894-A6A7-B41B83F5D3A9Q38732534-A4052B30-47B4-408B-9B28-D7AE6F31A747Q38755320-79F22DEC-C580-47D7-8E50-9D87E9BC4691Q38764956-E0769A80-2588-48EA-9C31-EC7A042164B5Q38822908-9620F28C-EB42-4017-A93B-1E25B0429A3FQ38893111-5B19B763-9C23-44B0-BCC0-48E41A31921BQ38932720-8ECFF3A8-F318-4D5D-B72F-756DB351F4D6Q39010896-9B120552-62B0-44E9-94C9-B768A90D422FQ39035646-8E182E96-B075-46D5-B8A0-1915836970B2Q39061922-BB9D2C75-203F-453C-BB02-57829A336859Q39118050-B689CDE7-8CB1-449B-BFEB-D043805ECB34Q39164127-C0CB1AE3-720E-427D-8492-531B8763B845
P2860
Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Predictors of new-onset heart ...... rsus reduced ejection fraction
@en
type
label
Predictors of new-onset heart ...... rsus reduced ejection fraction
@en
prefLabel
Predictors of new-onset heart ...... rsus reduced ejection fraction
@en
P2093
P2860
P50
P1476
Predictors of new-onset heart ...... rsus reduced ejection fraction
@en
P2093
Asya Lyass
Daniel Levy
Douglas S Lee
William B Kannel
P2860
P304
P356
10.1161/CIRCHEARTFAILURE.112.972828
P577
2012-12-27T00:00:00Z